The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).
J. Aisner
Research Funding - Cancer Institute of New Jersey
J. Manola
No relevant relationships to disclose
S. R. Dakhil
No relevant relationships to disclose
P. J. Stella
No relevant relationships to disclose
J. H. Schiller
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca